<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-17833" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Arsenical Keratosis</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Shajil</surname>
            <given-names>Chandana</given-names>
          </name>
          <aff>Christian Medical College and Hospital, Vellore, Tamil Nadu, India</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Chen</surname>
            <given-names>Philip</given-names>
          </name>
          <aff>University of Texas Health San Antonio</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Mahabal</surname>
            <given-names>Gauri D.</given-names>
          </name>
          <aff>Christian Medical College</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Chandana Shajil declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Philip Chen declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Gauri Mahabal declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>11</day>
          <month>8</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-17833.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Arsenical keratosis is a chronic skin condition resulting from prolonged exposure to arsenic, a toxic element in contaminated water, certain pesticides, and occupational settings. Characterized by thickened, rough, and sometimes wart-like lesions, typically on the palms and soles, arsenical keratosis is considered a precancerous condition due to its potential to develop into squamous cell carcinoma. The condition highlights the critical need for monitoring and controlling arsenic levels in the environment to prevent long-term health consequences. Diagnosis and management involve clinical awareness and evaluation with a high degree of suspicion, reduction of arsenic exposure, and regular dermatological assessments to monitor for malignancy.</p>
        <p>This activity reviews&#x000a0;the epidemiology, pathophysiology, clinical manifestations, diagnosis, and management strategies for arsenical keratosis. Participants learn about the sources and risks of arsenic exposure, the importance of early detection, and the latest advances in treatment and prevention. The review also highlights the role of an interprofessional healthcare team in enhancing diagnostic acumen and managing affected patients.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify&#x000a0;the pathophysiology of arsenical keratosis.</p></list-item><list-item><p>Assess&#x000a0;the typical presentation of a patient with arsenical keratosis.</p></list-item><list-item><p>Select&#x000a0;treatment options available for patients with arsenical keratosis.</p></list-item><list-item><p>Collaborate with&#x000a0;interprofessional team members to improve care coordination and clinical outcomes for patients affected by arsenical keratosis.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17833&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17833">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-17833.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Arsenical keratosis is a precancerous dermatosis&#x000a0;observed in patients with chronic arsenic toxicity.<xref ref-type="bibr" rid="article-17833.r1">[1]</xref> This condition is characterized by corn-like, yellowish, hyperkeratotic papules and plaques, primarily affecting the palms and soles. Often, it starts as small areas of hyperkeratosis, which increase in number and size to involve the entire palms and soles. In rare cases, it can spread to the dorsal surfaces of the hands and feet and other parts of the body and may progress to squamous cell carcinoma (SCC).</p>
        <p>Arsenical keratosis with skin hyperpigmentation is the earliest and most common presenting complaint in chronic arsenic toxicity.<xref ref-type="bibr" rid="article-17833.r2">[2]</xref><xref ref-type="bibr" rid="article-17833.r3">[3]</xref>&#x000a0;Therefore, it plays a crucial role in guiding clinicians toward the early diagnosis and treatment of chronic arsenic toxicity. Apart from benign conditions such as skin hyperpigmentation and Mees' lines in the nails, arsenical keratosis can sometimes coexist with single or multiple lesions of Bowen's disease, basal cell carcinoma, and SCC.<xref ref-type="bibr" rid="article-17833.r1">[1]</xref><xref ref-type="bibr" rid="article-17833.r4">[4]</xref>&#x000a0;Identification and elimination of the source of arsenic exposure are of utmost importance, as these patients are at a high risk of developing multisystem disorders and visceral malignancies.</p>
      </sec>
      <sec id="article-17833.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Arsenical keratosis is a cutaneous manifestation of arsenicosis, defined by the World Health Organization (WHO) as a chronic health condition resulting from the ingestion of arsenic above the safe limit for a minimum duration of 6 months.<xref ref-type="bibr" rid="article-17833.r5">[5]</xref><xref ref-type="bibr" rid="article-17833.r6">[6]</xref>&#x000a0;The time taken for skin lesions to appear depends on the physical and chemical form of arsenic, the route, dose, duration, and frequency of exposure, and can vary from anywhere between 4 years to 40 years.<xref ref-type="bibr" rid="article-17833.r7">[7]</xref><xref ref-type="bibr" rid="article-17833.r8">[8]</xref>&#x000a0;Inorganic arsenic is a ubiquitous element classified as a group&#x000a0;1 human carcinogen by the International Agency for Research on Cancer.<xref ref-type="bibr" rid="article-17833.r6">[6]</xref><xref ref-type="bibr" rid="article-17833.r9">[9]</xref>&#x000a0;Some of the well-recognized and documented sources of arsenic exposure are as follows:</p>
        <list list-type="bullet">
          <list-item>
            <p>Contaminated groundwater: Exposure occurs from drinking, cooking, and irrigating crops using contaminated well water.<xref ref-type="bibr" rid="article-17833.r10">[10]</xref><xref ref-type="bibr" rid="article-17833.r11">[11]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Food crops: Crops grown in contaminated soil or irrigated using&#x000a0;contaminated water can be a source of arsenic.<xref ref-type="bibr" rid="article-17833.r10">[10]</xref><xref ref-type="bibr" rid="article-17833.r11">[11]</xref>&#x000a0;Whole-grain rice is known to have higher arsenic levels compared to polished rice.&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
          </list-item>
          <list-item>
            <p>Medications: Fowler's solution (1% potassium arsenite) was used in the 20th century to treat various dermatoses and asthma.<xref ref-type="bibr" rid="article-17833.r7">[7]</xref>&#x000a0;In the early 1900s, until the advent of penicillin, arsenic-containing drugs, salvarsan and neosalvarsan, were used&#x000a0;to&#x000a0;treat syphilis.<xref ref-type="bibr" rid="article-17833.r12">[12]</xref> Currently,&#x000a0;arsenic trioxide is the only medicinal form of arsenic approved by the FDA&#x000a0;for treating relapsed or refractory acute promyelocytic leukemia.<xref ref-type="bibr" rid="article-17833.r13">[13]</xref><xref ref-type="bibr" rid="article-17833.r14">[14]</xref>&#x000a0;Arsenic&#x000a0;is also found in&#x000a0;Chinese herbal medicines and ayurvedic medicines.<xref ref-type="bibr" rid="article-17833.r15">[15]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Occupational exposures: Arsenic is used in the manufacture of alloys and the processing of pigments, textiles, glass, paper, hide (tanning process), wood preservatives, and ammunition. Workers involved in the smelting and mining of metals have greater exposure to arsenic compared to those engaged in manufacturing insecticides, pesticides, herbicides, pharmaceuticals, and poultry feeds. The population living close to these industries or mining activities is also at risk.<xref ref-type="bibr" rid="article-17833.r7">[7]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Tobacco: Tobacco plants can naturally absorb arsenic from contaminated soil&#x000a0;and insecticides. Cigarettes manufactured in the 1950s had high arsenic content, which has been gradually reduced to acceptable levels over the years. However, regulating the arsenic content in handmade cigarettes such as bidis has not yet been possible.<xref ref-type="bibr" rid="article-17833.r16">[16]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17833.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Arsenical keratosis is more commonly reported in countries with documented environmental arsenic contamination, particularly in groundwater. Affected countries include Bangladesh, India, Taiwan, Mexico, Chile, Argentina, Japan, and China.<xref ref-type="bibr" rid="article-17833.r10">[10]</xref><xref ref-type="bibr" rid="article-17833.r11">[11]</xref>&#x000a0;Many studies conducted in arsenic-endemic areas have found that with similar exposure to arsenic, men have an increased prevalence of arsenical keratosis compared to women.<xref ref-type="bibr" rid="article-17833.r17">[17]</xref>&#x000a0;The widely accepted explanation for this is the gender difference in the biomethylation of arsenic.<xref ref-type="bibr" rid="article-17833.r6">[6]</xref><xref ref-type="bibr" rid="article-17833.r8">[8]</xref>&#x000a0;Although arsenical keratosis can occur at any age, the incidence was higher in the older age group.<xref ref-type="bibr" rid="article-17833.r10">[10]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-17833.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Although the exact pathomechanism underlying the premalignant and malignant manifestations of chronic arsenic exposure is unknown, several hypotheses have been proposed. Arsenic metabolism in the body has a crucial role in most of these theories, which include the following:<xref ref-type="bibr" rid="article-17833.r10">[10]</xref><xref ref-type="bibr" rid="article-17833.r18">[18]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Genetic polymorphism of enzymes involved in the metabolic pathway; arsenite methyltransferase (AS3MT) is the primary mediator in the biomethylation of arsenic.<xref ref-type="bibr" rid="article-17833.r19">[19]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Global DNA hypomethylation is due to the depletion of S-adenosylmethionine in cells during arsenic biomethylation, leading to aberrant gene expression&#x000a0;and&#x000a0;carcinogenesis.<xref ref-type="bibr" rid="article-17833.r20">[20]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Reactive oxygen species generated during the metabolism of arsenic cause oxidative DNA damage, resulting in chromosomal abnormalities and sister chromatic exchange.<xref ref-type="bibr" rid="article-17833.r21">[21]</xref></p>
          </list-item>
        </list>
        <p>An individual's genetic susceptibility further facilitates the development of premalignant and malignant lesions. Key genetic factors include polymorphism in the DNA repair pathway genes, such as&#x000a0;<italic toggle="yes">ERCC2&#x000a0;</italic>and&#x000a0;<italic toggle="yes">XRCC3</italic>;&#x000a0;tumor suppressor genes, such as <italic toggle="yes">TP53</italic>;&#x000a0;glutathione S-transferase superfamily enzymes; IL10; TNF alpha; and NLRP2. Studies have shown an exaggerated expression of pro-inflammatory cytokines in chronic arsenic toxicity. Recent studies have revealed the role of arsenic-induced epigenetic alterations, which affect gene expression and&#x000a0;contribute to the development of premalignant dermatoses and malignancies.<xref ref-type="bibr" rid="article-17833.r18">[18]</xref> Thus, a complex interaction of&#x000a0;arsenic toxicodynamics with an individual's genetics leads to aberrations in cellular proliferation and differentiation, resulting in unregulated cell growth observed in arsenical keratosis and other tumors.</p>
      </sec>
      <sec id="article-17833.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Prominent features in the histopathological examination of arsenical keratosis include compact hyperkeratosis, parakeratosis, and acanthosis. Papillomatosis and vacuolated keratinocytes may be present. Keratinocyte atypia may or may not be observed, and its severity can vary from mild atypia to features of&#x000a0;SCC in situ,<xref ref-type="bibr" rid="article-17833.r22">[22]</xref><xref ref-type="bibr" rid="article-17833.r23">[23]</xref>&#x000a0;which is indistinguishable from Bowen's disease.<xref ref-type="bibr" rid="article-17833.r1">[1]</xref>&#x000a0;None of these histopathological features are specific to arsenical keratosis.</p>
        <p>Although biopsy does not confirm the diagnosis of arsenical keratosis, it is useful in detecting malignant transformation.<xref ref-type="bibr" rid="article-17833.r5">[5]</xref>&#x000a0;A similar histopathological picture can be observed in actinic keratosis, Bowen's disease, and verruca vulgaris; therefore, exposure history is essential in diagnosing arsenical keratosis.<xref ref-type="bibr" rid="article-17833.r8">[8]</xref></p>
      </sec>
      <sec id="article-17833.s7" sec-type="Toxicokinetics">
        <title>Toxicokinetics</title>
        <p>Arsenic is a metalloid element with atomic number 33 and naturally occurs in elemental, inorganic, organic, or gaseous forms. This element is most commonly silver-gray but can also be black or yellow. Arsenic is odorless&#x000a0;and tasteless and is a known&#x000a0;carcinogen.<xref ref-type="bibr" rid="article-17833.r7">[7]</xref><xref ref-type="bibr" rid="article-17833.r9">[9]</xref>&#x000a0;The inorganic forms of arsenic, especially arsenite (As<sup>3+</sup>), are more toxic to humans compared to the organic form found in seafood, such as fish and crustaceans.<xref ref-type="bibr" rid="article-17833.r1">[1]</xref><xref ref-type="bibr" rid="article-17833.r24">[24]</xref> Therefore, the risk of toxicity due to seafood consumption is negligible.<xref ref-type="bibr" rid="article-17833.r25">[25]</xref>&#x000a0;</p>
        <p>Arsenic enters the bloodstream predominantly through gastrointestinal absorption, although inhalation&#x000a0;and dermal absorption are also known to occur. A small portion of the absorbed arsenic is excreted unchanged in the urine. The major portion undergoes hepatic biomethylation to form monomethylarsonic acid and dimethyl arsenic acid, which are then excreted in the urine.<xref ref-type="bibr" rid="article-17833.r8">[8]</xref> This process leads to the rapid elimination of arsenic from the bloodstream. However, with chronic exposure, arsenic accumulates in the liver, kidneys, lungs, gastrointestinal tract, skin, and muscles due to its high affinity for sulfhydryl group-containing proteins and enzymes in these organs.<xref ref-type="bibr" rid="article-17833.r8">[8]</xref>&#x000a0;Most of the accumulated arsenic gets excreted over time; however, keratin-rich tissues such as nails, hair, and skin are exceptions.<xref ref-type="bibr" rid="article-17833.r25">[25]</xref></p>
      </sec>
      <sec id="article-17833.s8" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>The typical presenting complaints of arsenical keratosis include horny lesions&#x000a0;on the extremities, particularly affecting the palms and soles, which may be associated with pain and fissuring. The lesions are insidious in onset and gradually increase in size and number.</p>
        <p>On physical examination, multiple yellowish to pigmented hyperkeratotic papules and plaques that start over the pressure points on soles and palms are observed. As the disease progresses, the lesions increase in size, number, and thickness and can coalesce to form large verrucous plaques.<xref ref-type="bibr" rid="article-17833.r2">[2]</xref><xref ref-type="bibr" rid="article-17833.r6">[6]</xref>&#x000a0;There can be diffuse involvement of palms and soles, which can spread to the dorsal surfaces of hands, feet, and the rest of the body. Based on the thickness and size of the lesions, arsenical keratosis can be graded as follows:&#x000a0;<xref ref-type="bibr" rid="article-17833.r2">[2]</xref><xref ref-type="bibr" rid="article-17833.r6">[6]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Mild: Slight thickening of skin or papules of size &#x0003c;2 mm on a background skin with grit-like texture, best appreciated by palpation.&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
          </list-item>
          <list-item>
            <p>Moderate: Multiple raised, warty, keratotic, corn-like papules 2 to 5 mm in size.&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Severe: Keratotic papules of size &#x0003e;5 mm or confluent keratotic plaques, with or without fissures.</p>
          </list-item>
        </list>
        <p>Arsenical keratosis is often accompanied by pigmentary disturbances, manifesting as either generalized or diffuse hyperpigmentation or localized patchy hyperpigmentation, primarily involving the skin folds.<xref ref-type="bibr" rid="article-17833.r5">[5]</xref> Two striking patterns of pigmentation are observed in chronic arsenic toxicity&#x02014;symmetrically distributed hyperpigmented macules over the trunk and extremities described as a <italic toggle="yes">raindrop</italic>&#x000a0;pattern, and guttate hypopigmentation on a background of hyperpigmentation described as a <italic toggle="yes">raindrop on a dusty road</italic>&#x000a0;pattern. Oral mucosal pigmentation has also been described.<xref ref-type="bibr" rid="article-17833.r5">[5]</xref>&#x000a0;</p>
        <p>Aldrich-Mees lines are single or multiple transverse white bands traversing the entire width of the nail and involve the fingernails and toenails of patients.<xref ref-type="bibr" rid="article-17833.r1">[1]</xref>&#x000a0;In addition, individuals with arsenical keratosis may develop single or multiple lesions of Bowen's disease, SCC, and basal cell carcinoma over normal skin of exposed and&#x000a0;unexposed sites.<xref ref-type="bibr" rid="article-17833.r7">[7]</xref></p>
        <p>Chronic arsenic toxicity is a multisystem disorder, and patients with arsenical keratosis can have symptoms of chronic liver disease, chronic lung disease, distal sensorimotor neuropathy, peripheral vascular disease, ischemic heart disease, chronic kidney disease, and nonspecific gastrointestinal symptoms, such as anorexia, dyspepsia, and diarrhea.&#x000a0;In addition, patients may report headache, weakness, fatigue, redness of eyes (conjunctival congestion), and swelling of legs (non-pitting pedal edema). Diabetes and hypertension are prevalent in these patients.<xref ref-type="bibr" rid="article-17833.r2">[2]</xref><xref ref-type="bibr" rid="article-17833.r17">[17]</xref></p>
        <p>When evaluating a patient from an arsenic-endemic area presenting with acquired palmoplantar keratoderma, arsenical keratosis should be suspected. The clinician should assess for other skin manifestations and systemic symptoms associated with chronic arsenic toxicity and follow with appropriate laboratory investigations to confirm the diagnosis.<xref ref-type="bibr" rid="article-17833.r5">[5]</xref></p>
        <p>Arsenical keratosis typically manifests after years of arsenic exposure; therefore, a detailed history, which includes past, personal, medical, drug, and occupational details, is required to identify the source of arsenic exposure.<xref ref-type="bibr" rid="article-17833.r7">[7]</xref>&#x000a0;A history of similar skin or systemic complaints in other family members, the neighborhood, and the workplace suggests environmental exposure to arsenic.</p>
      </sec>
      <sec id="article-17833.s9" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>For patients presenting with skin lesions suggestive of arsenical keratosis, it is crucial to determine where and how they are being exposed to arsenic. Various methods for testing arsenic exposure include urine, hair, nail, and blood tests. Most arsenic testing does not differentiate between inorganic and organic arsenic; therefore, recent seafood ingestion can falsely elevate arsenic levels in samples tested. Speciation of arsenic can be performed to determine the contribution of organic arsenic better.<xref ref-type="bibr" rid="article-17833.r26">[26]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Estimation of arsenic concentration in urine: This evaluation indicates recent exposure to arsenic and should ideally be performed&#x000a0;with a 24-hour urine collection. An easier alternative is to test a spot or the first-morning urine sample. Both methods are comparable as the arsenic excreted remains stable throughout the day. Seafood containing the non-toxic organic form of arsenic should be avoided for at least&#x000a0;4 days before testing, as it can make the results unreliable. A concentration &#x0003e;50 &#x003bc;g/L proves recent exposure to arsenic.<xref ref-type="bibr" rid="article-17833.r5">[5]</xref><xref ref-type="bibr" rid="article-17833.r6">[6]</xref>&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
          </list-item>
          <list-item>
            <p>Estimation of arsenic concentration in hairs and nails: After washing hair with arsenic-free shampoo and ensuring the patient has not used any coloring agent, 30 hairs of 6 cm length from females and 60 hairs with the base from males are collected and tested. Nail clippings from all fingernails and toenails are also obtained. A concentration of arsenic &#x0003e;1 mg/kg of dry hair and &#x0003e;1.5 mg/kg of the nail indicates arsenic exposure in the preceding 9 months.<xref ref-type="bibr" rid="article-17833.r5">[5]</xref><xref ref-type="bibr" rid="article-17833.r6">[6]</xref></p>
          </list-item>
        </list>
        <p>Histopathological examination of the keratotic skin lesions should be performed to look for signs of malignant transformation. Still, because the histopathology is nonspecific to arsenic, it cannot be used to confirm arsenic toxicity.<xref ref-type="bibr" rid="article-17833.r5">[5]</xref></p>
        <p>Investigations should be directed toward establishing chronic arsenic toxicity in the patient and identifying the source of arsenic exposure, including the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Estimation of arsenic concentration in drinking water&#x000a0;or well water: An acid-washed plastic container is used to collect at least 50 mL of water to be tested. WHO has set a provisional guideline value of 10 &#x003bc;g/L for the maximum permissible concentration of arsenic in drinking water.<xref ref-type="bibr" rid="article-17833.r10">[10]</xref> However, countries such as India and Bangladesh follow the old guidelines and have a higher cut-off value of 50 &#x003bc;g/L.<xref ref-type="bibr" rid="article-17833.r5">[5]</xref>&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
          </list-item>
          <list-item>
            <p>Determination of&#x000a0;arsenic concentration in suspected sources, such as medications or pesticides, is carried out using atomic absorption spectrometry, calorimetric method, and spectrophotometry.<xref ref-type="bibr" rid="article-17833.r5">[5]</xref>&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Histopathological examination of the keratotic skin lesions is&#x000a0;performed to assess for malignant transformation, but it limited utility in confirming the diagnosis of arsenical keratosis.<xref ref-type="bibr" rid="article-17833.r5">[5]</xref></p>
          </list-item>
        </list>
        <p>Estimating arsenic concentration in drinking water is typically the first step in evaluating chronic arsenic toxicity. However, in clinical scenarios where drinking water data are unreliable, such as in a migratory population, analyzing&#x000a0;the patient's biological samples is crucial in establishing the diagnosis.</p>
      </sec>
      <sec id="article-17833.s10" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>After establishing arsenic toxicity in the patient and positively identifying the source of arsenic exposure, preventing further exposure forms the mainstay of treatment. Mild-to-moderate diseases have shown improvement in many such instances.<xref ref-type="bibr" rid="article-17833.r2">[2]</xref> Smoking and nutritional deficiencies are predisposing factors for this premalignant condition; therefore, patients should be advised to quit smoking and consume a well-balanced, high-protein diet.<xref ref-type="bibr" rid="article-17833.r10">[10]</xref>&#x000a0;Antioxidant supplementation, such as vitamins A, C, and E, is also believed to&#x000a0;potentially help in cancer prevention.<xref ref-type="bibr" rid="article-17833.r10">[10]</xref></p>
        <p>Treatment of arsenical keratosis is not mandatory;&#x000a0;instead, the goal is to provide supportive and symptomatic care to alleviate the patient's discomfort. There are no universally accepted standard guidelines for the treatment of arsenical keratosis. Treatment should be tailored to the patient's needs, disease severity, comorbidities, and pain tolerance. Various treatment options that have been explored over the years include:&#x000a0;<xref ref-type="bibr" rid="article-17833.r1">[1]</xref><xref ref-type="bibr" rid="article-17833.r6">[6]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Cryotherapy</p>
          </list-item>
          <list-item>
            <p>Curettage and electrodessication</p>
          </list-item>
          <list-item>
            <p>Carbon dioxide laser ablation</p>
          </list-item>
          <list-item>
            <p>Topical keratolytic agents, such as salicylic acid (5% to 10%) and urea (10% to 20%)</p>
          </list-item>
          <list-item>
            <p>Imiquimod 5% cream</p>
          </list-item>
          <list-item>
            <p>Topical 5-fluorouracil</p>
          </list-item>
          <list-item>
            <p>Oral retinoids</p>
          </list-item>
          <list-item>
            <p>Surgical excision</p>
          </list-item>
        </list>
        <p>Acitretin with topical keratolytic agents can be used to treat patients with extensive lesions and may offer chemoprevention for cancers associated with chronic arsenic toxicity.<xref ref-type="bibr" rid="article-17833.r1">[1]</xref><xref ref-type="bibr" rid="article-17833.r13">[13]</xref>&#x000a0;Patients should be instructed to apply imiquimod cream once daily for 6 weeks or 3 to 5 times per week for 8 weeks. Biannual clinic visits, annual chest radiographs, and selective tests based on symptoms are of utmost importance for the early detection of cutaneous and visceral malignancies.<xref ref-type="bibr" rid="article-17833.r16">[16]</xref></p>
      </sec>
      <sec id="article-17833.s11" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>When assessing&#x000a0;a patient with suspected arsenical keratosis, it is essential to consider a range of differential diagnoses to ensure accurate diagnosis and appropriate management. These conditions may present with similar clinical features, such as hyperkeratotic lesions on the palms and soles, and include both benign and malignant disorders.&#x000a0;The differential diagnoses to consider when assessing a patient for arsenical keratosis include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Verruca vulgaris</p>
          </list-item>
          <list-item>
            <p>Corns/calluses</p>
          </list-item>
          <list-item>
            <p>Dermatophyte infection</p>
          </list-item>
          <list-item>
            <p>Lichen planus</p>
          </list-item>
          <list-item>
            <p>Hyperkeratotic eczema</p>
          </list-item>
          <list-item>
            <p>Palmoplantar psoriasis</p>
          </list-item>
          <list-item>
            <p>Porokeratosis punctata palmaris et plantaris</p>
          </list-item>
          <list-item>
            <p>Clavi syphilitici</p>
          </list-item>
          <list-item>
            <p>Inherited palmoplantar keratoderma</p>
          </list-item>
          <list-item>
            <p>Spiny keratoderma</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17833.s12" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Arsenical keratosis is a precancerous condition and can progress to SCC. Although rare, SCC that arises in&#x000a0;arsenical keratosis is locally aggressive and demonstrates a greater metastatic potential compared to SCC arising in actinic keratosis.<xref ref-type="bibr" rid="article-17833.r1">[1]</xref><xref ref-type="bibr" rid="article-17833.r6">[6]</xref>&#x000a0;Studies have found that patients with arsenical keratosis are at a higher risk of subsequently developing bladder and lung cancer, likely secondary to chronic arsenic toxicity.<xref ref-type="bibr" rid="article-17833.r12">[12]</xref></p>
      </sec>
      <sec id="article-17833.s13" sec-type="Complications">
        <title>Complications</title>
        <p>Understanding the potential complications of arsenical keratosis is crucial for effective patient management and long-term care. If left untreated, this condition can lead to severe health issues beyond the skin, including systemic diseases and malignancies. Considerations of complications are as follows:</p>
        <list list-type="bullet">
          <list-item>
            <p>In extreme cases of arsenical keratosis, diffuse involvement of palms and soles with painful fissuring can occur,<xref ref-type="bibr" rid="article-17833.r6">[6]</xref>&#x000a0;which can be debilitating for the patient and impact daily activities and quality of life.&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Arsenical keratosis is&#x000a0;one of the several skin conditions that can be associated with a cutaneous horn.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Malignant transformation, typically SCC, should be suspected when there is a sudden increase in size, induration, fissuring, bleeding, inflammation, perilesional erythema, and ulceration.<xref ref-type="bibr" rid="article-17833.r1">[1]</xref><xref ref-type="bibr" rid="article-17833.r6">[6]</xref>&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Several organ systems can be affected in chronic arsenic toxicity, some leading to irreversible changes, chronic disease, and also predisposing to visceral malignancies.<xref ref-type="bibr" rid="article-17833.r1">[1]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17833.s14" sec-type="Consultations">
        <title>Consultations</title>
        <p>Caring for patients with arsenical keratosis necessitates a multidisciplinary approach involving various consultations to address the complex nature of the condition. Dermatologists play a crucial role in diagnosing and managing skin lesions and monitoring for malignant transformation. Oncologists may be required to evaluate and treat any associated malignancies, such as SCC. Toxicologists provide expertise in identifying and mitigating arsenic exposure sources. Nephrologists and hepatologists might be consulted to manage potential systemic effects on the kidneys and liver. In addition, occupational and environmental health specialists can offer guidance on preventing further exposure while primary care physicians coordinate overall patient care. This collaborative approach ensures comprehensive management, addressing both dermatological and systemic implications of chronic arsenic exposure.</p>
      </sec>
      <sec id="article-17833.s15" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Arsenical keratosis is an early cutaneous marker of chronic arsenic toxicity, a multisystem disorder with complications that can develop years after arsenic exposure.<xref ref-type="bibr" rid="article-17833.r5">[5]</xref> &#x000a0;Hence, in addition to steps preventing further exposure to arsenic, emphasis should be placed on regular follow-up to recognize and treat the cutaneous and extracutaneous manifestations of chronic arsenic toxicity at an early stage.</p>
        <p>Deterrence and patient education are pivotal in managing and preventing arsenical keratosis.&#x000a0;Educating patients about the sources of arsenic exposure, such as contaminated water, certain foods, and occupational hazards, is crucial for reducing risk. Patients should be informed about the importance of regular skin examinations, the early signs of arsenical keratosis, and the features of malignant transformation to facilitate prompt diagnosis and treatment.</p>
        <p>In addition, advising patients on using protective measures, such as water filtration systems and appropriate occupational safety practices, can significantly lower exposure levels. Smoking and nutritional deficiencies increase the chances of developing arsenical keratosis, and measures should be taken to mitigate these. Effective patient education empowers individuals to take proactive steps in mitigating their risk and ensures better health outcomes through early detection and intervention.</p>
      </sec>
      <sec id="article-17833.s16" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>Effective management of patients with arsenical keratosis hinges on several clinical pearls. Early recognition is paramount, as timely diagnosis can prevent progression to more severe conditions, including SCC. A detailed patient history is essential to identify potential sources of arsenic exposure, such as contaminated water or occupational hazards. Regular skin examinations are crucial for monitoring lesion changes and catching malignant transformations early. Integrating multidisciplinary care, including dermatologists, oncologists, and toxicologists, enhances patient outcomes. Patient education on minimizing arsenic exposure and adhering to treatment regimens significantly reduces the risk of complications. Utilizing a combination of topical treatments, systemic therapies, and lifestyle modifications can effectively manage symptoms and improve the quality of life for affected patients.</p>
      </sec>
      <sec id="article-17833.s17" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Addressing arsenical keratosis requires a comprehensive,&#x000a0;interprofessional approach to enhance patient-centered care, improve outcomes, ensure patient safety, and optimize team performance.&#x000a0;As it is an early manifestation of chronic arsenic toxicity, a missed diagnosis of arsenical keratosis can have adverse long-term outcomes.</p>
        <p>Patients with arsenical keratosis often present to their primary care&#x000a0;clinician. Clinicians&#x000a0;should be skilled in diagnosing and treating arsenical keratosis, recognizing its clinical manifestations, and understanding its progression and complications. These patients need to be referred for further diagnosis by a dermatologist as several skin diseases can be clinically similar, and a dermatologist can diagnose them based on the accompanying signs and risk factors.&#x000a0;Once diagnosed and initiated on treatment, the patient can be referred to their primary care&#x000a0;clinician for further management. A dermatopathologist has a vital role in management when a malignant transformation is suspected; if the histology reveals malignancy, surgical excision is&#x000a0;performed by a plastic surgeon.<xref ref-type="bibr" rid="article-17833.r5">[5]</xref></p>
        <p>Advanced practitioners should develop expertise in conducting thorough patient assessments, recognizing early signs, and implementing treatment plans. Nurses should be proficient in patient education, wound care management, and monitoring treatment efficacy and patient adherence. Pharmacists must have the skills to advise on appropriate pharmacological treatments, manage medication interactions, and educate patients on drug usage and&#x000a0;adverse effects. Other health professionals, such as dietitians and occupational therapists, should be equipped to offer guidance on lifestyle modifications and exposure prevention.</p>
        <p>Regular follow-up visits to identify systemic complaints and timely referral can lead to early diagnosis and treatment of associated systemic diseases, including malignancies. Hence, holistic management by an interprofessional healthcare team improves the outcomes of this multisystem disorder of public health significance.</p>
      </sec>
      <sec id="article-17833.s18">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17833&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17833">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/poisons/arsenical-keratosis-chronic-arsenic-toxicity/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=17833">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/17833/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=17833">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-17833.s19">
        <title>References</title>
        <ref id="article-17833.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schwartz</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Arsenic and the skin.</article-title>
            <source>Int J Dermatol</source>
            <year>1997</year>
            <month>Apr</month>
            <volume>36</volume>
            <issue>4</issue>
            <fpage>241</fpage>
            <page-range>241-50</page-range>
            <pub-id pub-id-type="pmid">9169318</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17833.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Guha Mazumder</surname>
                <given-names>DN</given-names>
              </name>
            </person-group>
            <article-title>Chronic arsenic toxicity &#x00026; human health.</article-title>
            <source>Indian J Med Res</source>
            <year>2008</year>
            <month>Oct</month>
            <volume>128</volume>
            <issue>4</issue>
            <fpage>436</fpage>
            <page-range>436-47</page-range>
            <pub-id pub-id-type="pmid">19106439</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17833.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Demissie</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mekonen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Awoke</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Teshome</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Mengistie</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Prevalence of arsenic-induced skin lesions and associated factors in Ethiopia: Community-based study.</article-title>
            <source>Toxicol Rep</source>
            <year>2023</year>
            <month>Dec</month>
            <volume>11</volume>
            <fpage>153</fpage>
            <page-range>153-161</page-range>
            <pub-id pub-id-type="pmid">37559672</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17833.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bhanja</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Sil</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sen</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Chandra</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Chronic arsenicosis.</article-title>
            <source>BMJ Case Rep</source>
            <year>2021</year>
            <month>Jul</month>
            <day>15</day>
            <volume>14</volume>
            <issue>7</issue>
            <pub-id pub-id-type="pmid">34266830</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17833.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Das</surname>
                <given-names>NK</given-names>
              </name>
              <name>
                <surname>Sengupta</surname>
                <given-names>SR</given-names>
              </name>
            </person-group>
            <article-title>Arsenicosis: diagnosis and treatment.</article-title>
            <source>Indian J Dermatol Venereol Leprol</source>
            <year>2008</year>
            <season>Nov-Dec</season>
            <volume>74</volume>
            <issue>6</issue>
            <fpage>571</fpage>
            <page-range>571-81</page-range>
            <pub-id pub-id-type="pmid">19171979</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17833.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ruiz de Luzuriaga</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Ahsan</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Shea</surname>
                <given-names>CR</given-names>
              </name>
            </person-group>
            <article-title>Arsenical keratoses in Bangladesh--update and prevention strategies.</article-title>
            <source>Dermatol Clin</source>
            <year>2011</year>
            <month>Jan</month>
            <volume>29</volume>
            <issue>1</issue>
            <fpage>45</fpage>
            <page-range>45-51</page-range>
            <pub-id pub-id-type="pmid">21095527</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17833.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maloney</surname>
                <given-names>ME</given-names>
              </name>
            </person-group>
            <article-title>Arsenic in Dermatology.</article-title>
            <source>Dermatol Surg</source>
            <year>1996</year>
            <month>Mar</month>
            <volume>22</volume>
            <issue>3</issue>
            <fpage>301</fpage>
            <page-range>301-4</page-range>
            <pub-id pub-id-type="pmid">8599743</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17833.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pratt</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wadden</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gulliver</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Arsenic Keratosis in a Patient from Newfoundland and Labrador, Canada: Case Report and Review.</article-title>
            <source>J Cutan Med Surg</source>
            <year>2016</year>
            <month>Jan</month>
            <volume>20</volume>
            <issue>1</issue>
            <fpage>67</fpage>
            <page-range>67-71</page-range>
            <pub-id pub-id-type="pmid">26239734</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17833.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tam</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Price</surname>
                <given-names>NE</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Molecular Mechanisms of Arsenic-Induced Disruption of DNA Repair.</article-title>
            <source>Chem Res Toxicol</source>
            <year>2020</year>
            <month>Mar</month>
            <day>16</day>
            <volume>33</volume>
            <issue>3</issue>
            <fpage>709</fpage>
            <page-range>709-726</page-range>
            <pub-id pub-id-type="pmid">31986875</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17833.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kapaj</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Peterson</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Liber</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Bhattacharya</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Human health effects from chronic arsenic poisoning--a review.</article-title>
            <source>J Environ Sci Health A Tox Hazard Subst Environ Eng</source>
            <year>2006</year>
            <volume>41</volume>
            <issue>10</issue>
            <fpage>2399</fpage>
            <page-range>2399-428</page-range>
            <pub-id pub-id-type="pmid">17018421</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17833.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rahaman</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Rahman</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Mise</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Sikder</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Ichihara</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Uddin</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Kurasaki</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ichihara</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Environmental arsenic exposure and its contribution to human diseases, toxicity mechanism and management.</article-title>
            <source>Environ Pollut</source>
            <year>2021</year>
            <month>Nov</month>
            <day>15</day>
            <volume>289</volume>
            <fpage>117940</fpage>
            <pub-id pub-id-type="pmid">34426183</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17833.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Centeno</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Mullick</surname>
                <given-names>FG</given-names>
              </name>
              <name>
                <surname>Martinez</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Page</surname>
                <given-names>NP</given-names>
              </name>
              <name>
                <surname>Gibb</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Longfellow</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ladich</surname>
                <given-names>ER</given-names>
              </name>
            </person-group>
            <article-title>Pathology related to chronic arsenic exposure.</article-title>
            <source>Environ Health Perspect</source>
            <year>2002</year>
            <month>Oct</month>
            <volume>110 Suppl 5</volume>
            <issue>Suppl 5</issue>
            <fpage>883</fpage>
            <page-range>883-6</page-range>
            <pub-id pub-id-type="pmid">12426152</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17833.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hinojosa</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Vandergriff</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Le</surname>
                <given-names>LQ</given-names>
              </name>
            </person-group>
            <article-title>Arsenical keratosis secondary to Fowler solution.</article-title>
            <source>JAAD Case Rep</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>4</volume>
            <issue>1</issue>
            <fpage>72</fpage>
            <page-range>72-74</page-range>
            <pub-id pub-id-type="pmid">29387754</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17833.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ozturk</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Metin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Altay</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Bhat</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Ejaz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gul</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Unal</surname>
                <given-names>BT</given-names>
              </name>
              <name>
                <surname>Hasanuzzaman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nibir</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Nahar</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Bukhari</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dervash</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Kawano</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Arsenic and Human Health: Genotoxicity, Epigenomic Effects, and Cancer Signaling.</article-title>
            <source>Biol Trace Elem Res</source>
            <year>2022</year>
            <month>Mar</month>
            <volume>200</volume>
            <issue>3</issue>
            <fpage>988</fpage>
            <page-range>988-1001</page-range>
            <pub-id pub-id-type="pmid">33864199</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17833.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Paul</surname>
                <given-names>NP</given-names>
              </name>
              <name>
                <surname>Galv&#x000e1;n</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Yoshinaga-Sakurai</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Rosen</surname>
                <given-names>BP</given-names>
              </name>
              <name>
                <surname>Yoshinaga</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Arsenic in medicine: past, present and future.</article-title>
            <source>Biometals</source>
            <year>2023</year>
            <month>Apr</month>
            <volume>36</volume>
            <issue>2</issue>
            <fpage>283</fpage>
            <page-range>283-301</page-range>
            <pub-id pub-id-type="pmid">35190937</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17833.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wong</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Goh</surname>
                <given-names>CL</given-names>
              </name>
            </person-group>
            <article-title>Cutaneous manifestations of chronic arsenicism: review of seventeen cases.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>1998</year>
            <month>Feb</month>
            <volume>38</volume>
            <issue>2 Pt 1</issue>
            <fpage>179</fpage>
            <page-range>179-85</page-range>
            <pub-id pub-id-type="pmid">9486671</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17833.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Guha Mazumder</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Dasgupta</surname>
                <given-names>UB</given-names>
              </name>
            </person-group>
            <article-title>Chronic arsenic toxicity: studies in West Bengal, India.</article-title>
            <source>Kaohsiung J Med Sci</source>
            <year>2011</year>
            <month>Sep</month>
            <volume>27</volume>
            <issue>9</issue>
            <fpage>360</fpage>
            <page-range>360-70</page-range>
            <pub-id pub-id-type="pmid">21914522</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17833.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Paul</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Majumdar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Giri</surname>
                <given-names>AK</given-names>
              </name>
            </person-group>
            <article-title>Genetic susceptibility to arsenic-induced skin lesions and health effects: a review.</article-title>
            <source>Genes Environ</source>
            <year>2015</year>
            <volume>37</volume>
            <fpage>23</fpage>
            <pub-id pub-id-type="pmid">27350818</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17833.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gonz&#x000e1;lez-Mart&#x000ed;nez</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>S&#x000e1;nchez-Rodas</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Varela</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Sandoval</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Qui&#x000f1;ones</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Johnson-Restrepo</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>As3MT and GST Polymorphisms Influencing Arsenic Metabolism in Human Exposure to Drinking Groundwater.</article-title>
            <source>Int J Mol Sci</source>
            <year>2020</year>
            <month>Jul</month>
            <day>08</day>
            <volume>21</volume>
            <issue>14</issue>
            <pub-id pub-id-type="pmid">32650499</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17833.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Saintilnord</surname>
                <given-names>WN</given-names>
              </name>
              <name>
                <surname>Fondufe-Mittendorf</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Arsenic-induced epigenetic changes in cancer development.</article-title>
            <source>Semin Cancer Biol</source>
            <year>2021</year>
            <month>Nov</month>
            <volume>76</volume>
            <fpage>195</fpage>
            <page-range>195-205</page-range>
            <pub-id pub-id-type="pmid">33798722</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17833.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lou</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Pi</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>The Role of Reactive Oxygen Species in Arsenic Toxicity.</article-title>
            <source>Biomolecules</source>
            <year>2020</year>
            <month>Feb</month>
            <day>05</day>
            <volume>10</volume>
            <issue>2</issue>
            <pub-id pub-id-type="pmid">32033297</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17833.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tian</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>FQ</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>GZ</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Iatrogenic Arsenism Characterized by Palmoplantar Hyperkeratosis and Diffused Skin Cancers for Over Decades.</article-title>
            <source>Am J Dermatopathol</source>
            <year>2021</year>
            <month>May</month>
            <day>01</day>
            <volume>43</volume>
            <issue>5</issue>
            <fpage>373</fpage>
            <page-range>373-376</page-range>
            <pub-id pub-id-type="pmid">33481374</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17833.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Khandpur</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Malhotra</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Bhatia</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>VK</given-names>
              </name>
              <name>
                <surname>Mishra</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Arora</surname>
                <given-names>NK</given-names>
              </name>
            </person-group>
            <article-title>Chronic arsenic toxicity from Ayurvedic medicines.</article-title>
            <source>Int J Dermatol</source>
            <year>2008</year>
            <month>Jun</month>
            <volume>47</volume>
            <issue>6</issue>
            <fpage>618</fpage>
            <page-range>618-21</page-range>
            <pub-id pub-id-type="pmid">18477160</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17833.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lepage</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Lescord</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Lock</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Johnston</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Gandhi</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gunn</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Biodilution of Organic Species of Arsenic in Freshwater Food Webs.</article-title>
            <source>Environ Toxicol Chem</source>
            <year>2024</year>
            <month>Apr</month>
            <volume>43</volume>
            <issue>4</issue>
            <fpage>833</fpage>
            <page-range>833-846</page-range>
            <pub-id pub-id-type="pmid">38146911</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17833.r25">
          <label>25</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Kuivenhoven</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mason</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <chapter-title>Arsenic Toxicity</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>6</month>
            <day>12</day>
            <pub-id pub-id-type="pmid">31082169</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17833.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wegwerth</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Erdahl</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Wermers</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Hanley</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Eckdahl</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Jannetto</surname>
                <given-names>PJ</given-names>
              </name>
            </person-group>
            <article-title>Reliable, Rapid, and Robust Speciation of Arsenic in Urine by IC-ICP-MS.</article-title>
            <source>J Appl Lab Med</source>
            <year>2021</year>
            <month>Jul</month>
            <day>07</day>
            <volume>6</volume>
            <issue>4</issue>
            <fpage>846</fpage>
            <page-range>846-857</page-range>
            <pub-id pub-id-type="pmid">33486508</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
